Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Depsipeptides/administration & dosage"'
Autor:
Enrique M. Ocio, Angelo Michele Carella, Maria-Victoria Mateos, Argiris Symeonidis, Heather Oakervee, Raymond H. Banh, Chang-Ki Min, Roman Hájek, Richard Greil, Pieter Sonneveld, Shang-Yi Huang, Carmen Kahatt, Ivan Spicka, Nathalie Meuleman, Sonia Extremera, James D'Rozario, Paul Cannell, Sara Martinez, Meletios A. Dimopoulos, Heinz Ludwig, Vicente Alfaro
Publikováno v:
Annals of Hematology
Annals of Hematology, 98(9), 2139-2150. Springer-Verlag
Annals of hematology
Annals of hematology, 98 (9
Annals of Hematology, 98(9), 2139-2150. Springer-Verlag
Annals of hematology
Annals of hematology, 98 (9
The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bca21caae1db2c673a339baafea4841c
https://doi.org/10.1007/s00277-019-03739-2
https://doi.org/10.1007/s00277-019-03739-2
Autor:
Philippe Aftimos, Andrea Varga, Jean-Charles Soria, Ahmad Awada, Sandrine Aspeslagh, Arturo A.S. Matos-Pita, Rastilav Bahleda
Publikováno v:
Anti-Cancer Drugs. 27:1021-1027
This phase I trial evaluated the toxicity profile and maximum tolerated dose of the combination between the marine derived cyclodepsipeptide plitidepsin and bevacizumab in advanced cancer patients. Thirteen patients were enrolled and treated with pli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66e5e5c9672f1bb68254623f67ae21b3
https://doi.org/10.1097/cad.0000000000000409
https://doi.org/10.1097/cad.0000000000000409
Autor:
Antoine Hollebecque, Sonia Extremera, Gilles Salles, Vicente Alfaro, Sandrine Aspeslagh, Mark N. Stein, Emmanuel Gyan, Salvador Fudio, Rastilav Bahleda, Arturo Soto-Matos, Jean-Charles Soria
Publikováno v:
Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩
International audience; This phase I trial evaluated the combination of the marine-derived cyclodepsipeptide plitidepsin (trade name Aplidin) with sorafenib or gemcitabine in advanced cancer and lymphoma patients. The study included two treatment arm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23b85d24896c8e6b050b4cfb9ec050c
https://hal.archives-ouvertes.fr/hal-01791282
https://hal.archives-ouvertes.fr/hal-01791282
Autor:
Sara K. Nissen, Giuseppe Pantaleo, Maja A. Sommerfelt, Mariane H. Schleimann, Rikke Olesen, Anne Sofie Høgh Kølbæk Kjær, Christel R. Brinkmann, Kim Krogsgaard, Kersten K. Koelsch, William J. Hey-Cunningham, Paul W. Denton, Ole S. Søgaard, Nicolas Chomont, Rémi Fromentin, Mette E. Graversen, Steffen Leth, Martin Tolstrup, Thomas A Rasmussen, Lars Østergaard
Publikováno v:
Plos Pathogens, vol. 11, no. 9, pp. e1005142
Søgaard, O S, Graversen, M E, Leth, S, Olesen, R, Brinkmann, C R, Nissen, S K, Kjaer, A S, Schleimann, M H, Denton, P W, Hey-Cunningham, W J, Koelsch, K K, Pantaleo, G, Krogsgaard, K, Sommerfelt, M, Fromentin, R, Chomont, N, Rasmussen, T A, Østergaard, L J & Tolstrup, M 2015, ' The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo ', P L o S Pathogens, vol. 11, no. 9, e1005142, pp. 1-22 . https://doi.org/10.1371/journal.ppat.1005142
PLoS Pathogens, Vol 11, Iss 9, p e1005142 (2015)
Søgaard, O S, Graversen, M E, Leth, S, Olesen, R, Brinkmann, C R, Nissen, S K, Kjaer, A S, Schleimann, M H, Denton, P W, Hey-Cunningham, W J, Koelsch, K K, Pantaleo, G, Krogsgaard, K, Sommerfelt, M, Fromentin, R, Chomont, N, Rasmussen, T A, Østergaard, L J & Tolstrup, M 2015, ' The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo ', P L o S Pathogens, vol. 11, no. 9, e1005142, pp. 1-22 . https://doi.org/10.1371/journal.ppat.1005142
PLoS Pathogens, Vol 11, Iss 9, p e1005142 (2015)
UnlabelledPharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90ff5e3d2ca27a7ecdd7ba1489504abe
https://pubmed.ncbi.nlm.nih.gov/26645606
https://pubmed.ncbi.nlm.nih.gov/26645606